Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (720)	5/14/1999 10:50:00 AM
From: Claude Robitaille	Read Replies (1) \| Respond to of 2344

Hi! Can you tell me the meaning of DD I am french and I can't figured out this abreviation. Thanks!

To: Silver Knife who wrote (720)	5/14/1999 12:09:00 PM
From: StockMiser	Read Replies (1) \| Respond to of 2344

Things to come (off the Yahoo board...) ----------------- Did anyone notice the timeframes for MATX? Fast Track means that the FDA will review data in 6 months. MATX won't even have any data to review until late next year. Biomira could make a similar announce at any moment. In fact, fast track can even be applied for PRIOR to start of phase 3. The current P3 trial is designed with fast track in mind, with data available for review every 6 months (by an independent entity so as to not violate dbl-blind). Some data could be available for review early next year (yes, prior to MATX). Also just read on SI that Theratope does, indeed, include milestone payments. News of this should appear at full enrollment and other benchmarks. So...we got this weekend: - (3) Theratope studies (stem cell replacement for breast and ovarian, and the bridging study) - Probable NY Times article on cancer vaccines (interview confirmed) - Possible Barrons, Science Times, and other publication coverage - Possible mainstream media coverage for a very HOT subject: stem cell therapy and breast cancer (it WORKS with Theratope, but not with chemo - extremely newsworthy!) - Possible additional broker coverage and analysis (ala IMCL) Slightly longer term: - Strategic alliance for BLP-25 development/marketing - Start of P2 clinical trials BLP-25/BLP-16 - Start of P1 trials on Lipo vaccine with Biovector - Announcement of Chiron milestone payments (Theratope) - Announcement of "fast track" filing - Possible start of P3 trials Theratope for ovarian and colorectal cancers Lots and lot of great news...for a great company....doing great things. They save lives....we make money. What more could ya want? IP ---------- BIOM investors Club: clubs.yahoo.com